Can you review the current evidentiary basis for the deployment of dupilumab in pediatric and adolescent age groups, and how clinical outcomes, time to resolution, and dosing consideration compare to results reported in the original trials in adults?
Can you review the current evidentiary basis for the deployment of dupilumab in pediatric and adolescent age groups, and how clinical outcomes, time to resolution, and dosing consideration compare to results reported in the original trials in adults?
Presenter
Clinical Assistant Professor of Dermatology and Pediatrics
Feinberg School of Medicine
Northwestern University
Chicago, Illinois